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Abstract
Dopa decarboxylase (DDC), a pyridoxal 59-phosphate (PLP) enzyme responsible for the biosynthesis of dopamine and
serotonin, is involved in Parkinson’s disease (PD). PD is a neurodegenerative disease mainly due to a progressive loss of
dopamine-producing cells in the midbrain. Co-administration of L-Dopa with peripheral DDC inhibitors (carbidopa or
benserazide) is the most effective symptomatic treatment for PD. Although carbidopa and trihydroxybenzylhydrazine (the in
vivo hydrolysis product of benserazide) are both powerful irreversible DDC inhibitors, they are not selective because they
irreversibly bind to free PLP and PLP-enzymes, thus inducing diverse side effects. Therefore, the main goals of this study
were (a) to use virtual screening to identify potential human DDC inhibitors and (b) to evaluate the reliability of our virtual-
screening (VS) protocol by experimentally testing the ‘‘in vitro’’ activity of selected molecules. Starting from the crystal
structure of the DDC-carbidopa complex, a new VS protocol, integrating pharmacophore searches and molecular docking,
was developed. Analysis of 15 selected compounds, obtained by filtering the public ZINC database, yielded two molecules
that bind to the active site of human DDC and behave as competitive inhibitors with Ki values $10 mM. By performing in
silico similarity search on the latter compounds followed by a substructure search using the core of the most active
compound we identified several competitive inhibitors of human DDC with Ki values in the low micromolar range, unable to
bind free PLP, and predicted to not cross the blood-brain barrier. The most potent inhibitor with a Ki value of 500 nM
represents a new lead compound, targeting human DDC, that may be the basis for lead optimization in the development of
new DDC inhibitors. To our knowledge, a similar approach has not been reported yet in the field of DDC inhibitors
discovery.
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Introduction
Parkinson’s disease (PD) is the most extensively studied
pathology within a group of syndromes called ‘‘motor system
disorders’’, whose etiology can be traced back to the loss of
dopaminergic neurons of the substantia nigra in the midbrain [1].
Main symptoms of PD include tremors, rigidity, bradykinesia and
postural instability; other frequently observed symptoms include
depression and other psychiatric disorders, difficulty in swallowing,
chewing, and speaking. Early symptoms of PD are usually subtle
and occur gradually after 50 years of age. As the symptoms
become more severe, patients progressively encounter difficulties
in walking, talking, or even completing the simplest tasks; usually,
this condition interferes strongly with most daily activities.
At present there is no cure for PD, but a variety of palliatives
reducing the severity of disease symptoms exists [2]. In order to
replenish dopamine levels at the central nervous system (CNS), L-
Dopa is usually administered. The latter is converted to dopamine
by Dopa decarboxylase (DDC, E.C. 4.1.1.28), a pyridoxal-59-
phosphate (PLP)-dependent enzyme, which is abundant in the
CNS and in the kidney [3]. DDC from pig kidney has been widely
characterized with respect to reaction and substrate specificity
[4,5], spectroscopic features of the internal aldimine and of
enzyme-intermediate complexes [6,7,8], and the role played by
residues at or near the active site in the catalysis [9,10,11,12].
Moreover, the crystal structures of DDC, both ligand-free and in
complex with the antiParkinson drug carbidopa, have been solved
[13].
Although administration of exogenous L-Dopa to PD patients
compensates, at least transitorily, for deficiency of dopamine
synthesis and often provides dramatic relief from the main
symptoms, only 1–5% of L-Dopa reaches the dopaminergic
neurons of the brain, being the major part metabolized by the
peripheral DDC. Therefore, in order to increase the amount of L-
Dopa in the CNS, DDC inhibitors unable to cross the blood-brain
barrier (BBB) are usually co-administered with L-Dopa. In this
way, not only greater amounts of L-Dopa can reach the brain,
thereby substantially increasing its level, but also side effects, either
dopamine-related or due to a high concentration of L-Dopa in the
blood stream, are diminished [1]. The most commonly used DDC
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3inhibitors in the treatment of PD are carbidopa (L-a-methyl-a-
hydrazino-3,4-dihydroxyphenylpropionic acid, MK 485) and
benserazide (trihydroxybenzylhydrazine seryl derivative, Ro-4-
4602). Pharmacokinetic and metabolic studies in animals and
humans have shown that benserazide is completely metabolized
before it reaches the arterial blood and that the main metabolic
pathway consists of the scission of the molecule between serine and
trihydroxybenzylhydrazine (Ro 4-5127) [14]. Thus, it is likely that
trihydroxybenzylhydrazine represents the actual DDC inhibitor.
Indeed, while benserazide is not a powerful DDC inhibitor [15],
carbidopa and trihydroxybenzylhydrazine, both substrate analogs
endowed with a substituted hydrazine function, have been found
to bind to pig kidney DDC by forming a hydrazone linkage with
PLP and work as powerful irreversible DDC inhibitors [16,17].
Nevertheless, because hydrazine derivatives can react with free
PLP and PLP-enzymes, these inhibitors are not entirely selective
for DDC, thus resulting in adverse side effects [18,19]. Although
the crystal structure of DDC has been solved ten years ago, no
structure-based design studies have been reported to date. Thus, in
order to identify competitive and highly selective DDC inhibitors,
we decided to undertake a virtual screening (VS) approach
combined with in vitro binding experiments.
As a starting point, the structure of pig kidney DDC (,90%
sequence identity with human DDC) in complex with the inhibitor
carbidopa (PDB code: 1JS3 [13]) was used to identify the essential
features required for DDC binding. Then, a pharmacophore
model was generated and validated using an in-house built
database of known active and inactive DDC inhibitors, derived
from Hartman et al. [20]. The pharmacophore model was first
used to filter the lead-like and the drug-like subsets of the public
ZINC database (,8 million compounds [21]) which are tailored to
an extended Lipinski’s rule of five [22]. Compounds satisfying the
pharmacophoric requirements were then instrumental to run
docking studies. Hence, compounds showing the highest binding
scores were selected, and tested in vitro for their ability to bind and
inhibit purified recombinant human DDC. The compounds with
the highest inhibitory activity were used to perform a second
similarity-based filtering of the public ZINC database to retrieve
analogs in order to expand the new classes of DDC inhibitors. The
in vitro testing revealed that 9 hits sorted out from the second
screening inhibit human DDC in a competitive mode with Ki
values in the range 2–15 mM. Subsequently, from a substructure
search using the core of the most active compound, a molecule
with a Ki value of 500 nM emerged as a promising candidate for
further lead optimization.
Results
Virtual Screening
On the basis of the crystal structure of pig kidney DDC (PDB
code: 1JS3) in complex with the anti-Parkinson drug carbidopa,
the key chemical features responsible for the critical binding
interactions were initially derived. A pharmacophore query was
used to build a 8-points pharmacophore hypothesis (PH)
containing: (1) an aromatic centroid (F1, Aro) located at the
geometric center of the catechol ring and its normal projection
(F2, PiN), which points at Lys303, (2) a hydrogen bond donor
feature (F3, Don) located on the para-hydroxyl substituent of the
catechol moiety and its projection (F4, Don2), which points at the
side chain of Thr82, (3) a hydrogen bond donor feature (F5, Don)
on the meta-hydroxyl substituent of the catechol moiety and its
projection (F6, Don2), which points at the phosphate moiety of the
PLP cofactor, and (4) a hydrogen bond acceptor feature (F7, Acc)
located on the oxygen of the carboxylate group and its projection
(F8, Acc2), which points at the side chain of His192. Finally, in
order to take into account the shape of the active site of DDC, a
steric constraint (excluded volume) was derived from the DDC-
carbidopa complex and included in the PH. Such features are
summarized in Table 1.
Then, within a set of already experimentally tested compounds
[20], those showing no chirality center were included in a training
set. On the basis of assays performed on a pig kidney extract [20],
they were clustered in inactive (31 compounds causing a loss of
DDC activity ,10% at 2.2 mM concentration), poorly active (33
compounds causing a loss of DDC activity $10% at 2.2 mM
concentration), moderately active (29 compounds causing a loss of
DDC activity $10% at a concentration in the range 220–
440 mM), and highly active (9 compounds causing a loss of DDC
activity $10% at a concentration ,110 mM). All active molecules
(i.e., poorly, moderately and highly active compounds) were
analyzed with the previously developed PH and the conformations
of the matching molecules were processed in order to retrieve
consensus chemical features (coordinates, radius and feature type).
The latter, in turn, were included in the PH (as detailed in the
‘‘Materials and Methods section’’). For this purpose, the
annotation points of the active compounds matching the PH
were clustered in ten chemical features (C1–C10, Table 1). C1–C8
coincided with F1–F8 in terms of position (root mean square
deviation (RMSD): 0.13 A ˚) and type of feature, even if the radii of
the spheres were slightly different (Table 1). Moreover, two new
chemical features were identified: a hydrogen bond acceptor
projection feature (C9) roughly pointing at His302 and a hydrogen
bond acceptor projection feature (C10) pointing at two structural
water molecules (hydrogen bonded to the carboxylate moiety of
carbidopa in the DDC-carbidopa complex). The two new
projection features, C9 and C10, were then added to the initial
PH, and the radii of all the chemical features, F1 to F8, were
subsequently adapted according to the values calculated by the
consensus function for the C1–C8 features. Therefore, in order to
assess which features could be regarded as essential for the
subsequent pharmacophore searches (PSs), we generated several
alternative PHs, each containing all but one feature, and
compared their performance by carrying out PSs of the final
training set (initial training set plus 1950 decoys; see ‘‘Materials
and Methods section’’ for further details). The final obtained PH
Table 1. Chemical features in the PHs.
Atoms Feature pig DDC - carbidopa Feature Final PH
Catechol ring F1 Aro (1)
E C1 Aro (1.57)
E
F2 PiN (1.4) C2 PiN (1.58)
Meta-OH F3 Don (1) C3 Don (1.28)
E
F4 Don2 (1.4) C4 Don2 (1.49)
Ortho-OH F5 Don (1) C5 Don (1)
F6 Don2 (1.4) C6 Don2 (1.2)
Carboxylate F7 Acc (1) C7 Acc (1.49)
F8 Acc2 (1.4) C8 Acc2 (1.37)
Active compounds C9 Acc2 (1.58)
E
C10 Acc2 (1.29)
The table summarizes the type of chemical feature, its location in the initial PH,
derived from the pig kidney DDC – carbidopa complex, and in the final PH. The
features which were regarded as essential are shown. Numbers in parenthesis
indicate the sphere radii of each feature (A ˚).
EEssential.
doi:10.1371/journal.pone.0031610.t001
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48% active (30% poorly active, 55% moderately active and 88%
highly active) and 6% inactive compounds, thus clearly showing a
marked improvement as compared to the initial PH, with 27%
active (12% poorly actives, 34% moderately active and 55% highly
active) and 3% inactive compounds.
The final PH was then used to filter the drug-like and lead-like
subsets of the ZINC database [21]. This PS retrieved ,280000
drug-like and ,180000 lead-like molecules, matching at least 6
chemical features. These virtual hits underwent a second docking-
based filtering by means of the Dovis docking tool [23,24]. All the
potential hits (,460000) were docked into the active site of DDC,
and the normal distribution of their scores (reported as predicted
pKi values) was derived. The distributions of scores for lead-like
and drug-like molecules showed a mean pKi of 5.3060.62 and
5.5760.81, respectively (Fig. S1 and S2). 2391 drug-like and 2994
lead-like molecules with significant scores ($2 standard deviations
(SDs from mean) were selected and resubmitted to a further
docking step by means of a second docking tool, Autodock Vina
[25]. 1496 and 1763 drug-like and lead-like compounds,
respectively, showed poses comparable when docked with both
Vina and Dovis (RMSD value #2A ˚). Of these, 17 lead-like and
44 drug-like molecules (whose ZINC code and final ranking are
reported in Supplementary Tables S1 and S2) fulfilled also the
restraints imposed by the final PH. Then, the similar compounds
were clustered, and, on the basis of the predicted pKi and the
commercial availability, the most potent of each group was
chosen. This protocol gave us 7 drug-like and 8 lead-like molecules
that were subjected to in vitro testing. For each compound the
chemical structure is reported in Fig. 2 and the number of
matched features of the final PH in Table 2.
Inhibition and binding analysis
The 15 compounds resulting from the virtual screening were
tested for their ability to bind to and inhibit human recombinant
DDC. At a concentration in which their solubility was maximum,
compounds 6, 8, 13, and 15 do not inhibit DDC activity,
compounds 3, 4, 7, 9 and 14 exhibit weak DDC inhibition activity
(8–25%), while the compound 12 exerts an inhibitory effect of
DDC activity of ,55%. On the other hand, the remaining
compounds 1, 2, 5, 10 and 11 inhibit DDC by 70% or more. An
IC50 analysis performed on the latter molecules identified five
inhibitors of human DDC with well-behaved IC50 curves giving
IC50 values equal to 570666 mM, 15006220 mM, 124697 mM,
12.860.4 mM, and 27.361.6 mM for compounds 1, 2, 5, 10 and
11, respectively. The IC50 curve of compound 11 is shown in Fig.
S3A. These molecules and also compound 12 were further
analyzed in order to identify the type of inhibition. Compounds 1,
2, 5, 11 behave as typical reversible inhibitors with competitive
inhibition, compound 10 with mixed inhibition, and compound
12 with noncompetitive inhibition. The inhibition constant values
(Ki and/or Ki9) for each of these inhibitors are reported in Table 2.
None of the competitive inhibitors changed the absorbance
spectrum of free PLP. On the other hand, the addition of any of
the competitive inhibitors to human DDC induced a modification
of the CD spectrum which, like in the pig kidney enzyme [26], is
characterized by positive dichroic bands at 420 and 335 nm. The
modification consists of a decrease of the 420 nm positive signal
and a concomitant increase of the 335 nm positive band. The
fractional changes in the magnitude of the 420 nm or the 335 nm
dichroic band as a function of the compound 1, 2, 5 and 11
concentrations were used to calculate the KD for the inhibitor-
DDC complexes formation. The KD values were found to be
240668 mM, 5166126 mM, 54.969.8 mM and 16.162.1 mM, for
compounds 1, 2, 5, and 11, respectively, in good agreement with
the corresponding Ki values. Taken together, these data strongly
suggest that all the competitive inhibitors bind to the human DDC
active site.
As shown in Fig. 3, the computational docking for compounds
1, 2, 5, and 11 gives the following clues regarding the possible
binding mode:
Compound 1 (Fig. 3A). The 1-hydroxybenzotriazole ring of
this compound shows a cation - p interaction with Lys303. The
nitrogen atom and the hydroxylic group of the 1-
Figure 1. Pharmacophore hypothesis of a competive inhibitor of DDC, superimposed on the 1JS6 – carbidopa complex. The chemical
features of the final pharmacophore essential for the binding of a competitive inhibitor to DDC are shown as spheres. Carbidopa is represented as
balls and sticks. PLP, water molecules and residues interacting with carbidopa are also shown and labeled.
doi:10.1371/journal.pone.0031610.g001
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doi:10.1371/journal.pone.0031610.g002
Table 2. Lead-like (compounds 1, 2, 4, 6, 8, 10, 14, 15) and drug-like (compounds 3, 5, 7, 9, 11, 12, 13) molecules selected by the VS.
ZINC code Ambinter
MW
(Da) Matched features
Ki
a
Ki9
b
(mM) BE Inhibition profile
1 02654612 T5246255 333 5 10667
a 11.9 Competitive
2 03324540 T0516-9932 282 5 390630
a 12.1 Competitive
3 05936951 T5347527 381 4 n.d. - n.d.
4 00408890 STOCK1N-01831 295 4 n.d. - n.d.
5 05252718 T5607516 412 4 59.865.8
a 10.2 Competitive
6 00111962 STOCK1N-14396 326 7 n.d. - n.d.
7 12603254 T5999596 351 6 n.d. - n.d.
8 03243721 T0511-4207 332 5 n.d. - n.d.
9 05185571 T6014881 407 5 n.d. - n.d.
10 00492694 STOCK1S-02871 266 7 6.0360.55
a
23.161.1
b
- Mixed
11 08042801 PB-05725216 381 6 10.762.4
a 13.0 Competitive
12 01874906 STOCK3S-99912 459 9 19.461.4
b - Noncompetitive
13 07986167 T5522252 375 5 n.d. - n.d.
14 00342069 STK059041 322 5 n.d. - n.d.
15 00134865 F0433-0503 316 5 n.d. - n.d.
The table summarizes, for each compound, the ZINC-code, the Ambinter-code, the molecular weight, the number of matched features of the final PH, the experimental
Ki and/or Ki9 values, the BE, and the inhibition profile. n.d., not determined.
doi:10.1371/journal.pone.0031610.t002
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the phosphate of the PLP cofactor, respectively. The sulfonamidic
nitrogen atom interacts with one of the water molecules bridging
the phosphate group of PLP and His192. Moreover, the 3-
carboxy-phenyl ring displaces the second water molecule, and
interacts with Phe1039 (showing a parallel-displaced stacking
arrangement) and Leu3539 (accent indicates residues of the active
site provided by the adjacent monomer). Finally, the carboxylic
group of this ring is hydrogen bonded to Ser193.
Compound 2 (Fig. 3B). The 1-hydroxybenzotriazole ring
interacts similarly to the one of compound 1. One of the oxygen
atoms of the sulfonamidic group is hydrogen bonded with the two
water molecules interacting with the carboxylic group of
carbidopa in the carbidopa-DDC-complex. The piperidinic ring
interacts hydrophobically with the residues Tyr79, Phe80 and
Thr246.
Compound 5 (Fig. 3C). The 2-carbonyl-2,3-dihydro-
benzimidazole ring of this compound shows a cation- p
interaction with Lys303, and its nitrogen and carbonyl atoms
interact with the amide carbonyl of Pro81 and with Thr82,
respectively. Furthermore, the oxygen atoms of the sulfonamidic
group interact with several water molecules, which interact with
the carboxylic group of carbidopa in the carbidopa-DDC
complex. In particular, one of the oxygen atoms is hydrogen
bonded to the water molecules bridging the phosphate group of
PLP and His192, and the other sulfonamidic oxygen atom is
hydrogen bonded to one of the two solvent exposed water
molecules. The amidic carbonyl moiety interacts with His192 and
a water molecule. Finally, the two aromatic rings, benzene and
furan, show hydrophobic interactions with Phe1039, Leu3539,
Tyr79, Phe80 and Thr246.
Compound 11 (Fig. 3D). The aromatic catechol ring of this
compound approximately overlaps with the catechol ring of
carbidopa (and, possibly with the one of L-Dopa) and, similarly
to the latter, it shows a cation- p interaction with Lys303. The
ortho and meta hydroxyl groups of the catechol ring are hydrogen
bonded to the phosphate moiety of the PLP cofactor and to
Thr82, respectively. The catechol is connected to a 3-mercapto-
Figure 3. Predicted binding mode of compounds selected after the first VS. The figure shows the binding mode of (A) compound 1, (B)
compound 2, (C) compound 5, and (D) compound 11. Residues and water molecules interacting with the inhibitors are also shown. Figure was
rendered with Pymol (http://www.pymol.org/).
doi:10.1371/journal.pone.0031610.g003
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moiety. The N1 atom of the heterocycle is hydrogen bonded
to His192, and the thiol group to the phosphate moiety of
the PLP cofactor. The heterocycle is well positioned to displace
the water molecules (which were found to interact with
carbidopa in the crystal structure of the carbidopa-DDC
complex; PDB code: 1JS3) bridging the phosphate group of
PLP and His192. The triazole ring and the 2,4-dichloro-phenyl
ring show hydrophobic interactions with several residues located
at the opposite sides of the active site entrance, namely Phe1039
and Leu3539, as well as Tyr79, Phe80 and Thr246. Moreover,
the triazole ring and Phe1039 show a parallel-displaced stacking
arrangement.
Second Screening (Similarity Search)
Following the initial identification of active compounds, a
similarity search was carried out by using the most potent hits
(compounds 5 and 11) as query. First, starting from the ZINC
database of small molecules, a fingerprinted database was
generated, and then the two identified compounds were used as
a query to find similar compounds. To this end, the MACCS
structural keys [27] and the Tanimoto coefficient (TC) [28] were
used as fingerprint system and similarity metric, respectively.
Then, each compound was ranked according to the TC,
calculated with respect to the query, and those showing a
TC.0.80 were selected and further filtered on the basis of the
commercial availability. The candidate molecules related to
compound 5 showed variations limited to the 2-(((furan-2-yl)-
methylamino)-carbonyl) moiety (namely ZINC03886086 and
ZINC22621067). On the other hand, a series of compounds
showing variations on substitution pattern of either the hydroxyl
groups on the catechol ring or the halogen atoms on the second
aromatic ring has been selected among the molecules related to
compound 11. This procedure was adopted in an attempt to
obtain information on the structure/activity relationship of the
above mentioned positions. To this end, two molecules from the
Ambinter database, which did not figure in the ZINC database,
were also selected. This procedure gave two molecules related to
compound 5 and twenty molecules related to compound 11 (see
Table S3 and S4 for the ranking of the selected compounds). All of
them, whose structures are shown in Fig. 4, were subjected to in
vitro testing.
Inhibition and binding analysis
To probe the reliability of this second screening we tested the
effect of the 22 compounds on human DDC activity using the ‘‘in
vitro’’ assay. The decarboxylase activity was determined in the
absence and in presence of each compound, and IC50 values were
determined for compounds 17, 21, 22, 23, 24, 25, 28, 30, 31, 34,
35, and 37 (Table 3). Dose-response curves of compounds 17, 21,
23, 25, 34, and 37 are reported in Fig. S3A. It was not possible to
define the IC50 values for the remaining compounds since at a
concentration in which their solubility was maximum they inhibit
DDC activity less than 55%. The analysis of the inhibition profile
reveals that compounds 16, 17, 18, 20, 21, 23, 24, 25, 28, 30,
31, 34, and 37 behave as competitive inhibitors of human DDC,
while compounds 22, 27, 29, 32, and 33 inhibit decarboxylase
activity in a mixed mode, and compounds 26 and 35 are
noncompetitive inhibitors. The Ki and/or Ki9 values of these
inhibitors are listed in Table 3. Changes in the CD bands of the
visible spectrum of DDC induced by the addition of each of the
competitive inhibitors are indicative of their binding to the active
site of the enzyme. Compounds 21 and 34 cause a decrease of the
420 nm dichroic signal and a concomitant appearance of a
positive dichroic signal at 388 nm as well as an increase of the
335 nm dichroic band, while the remaining competitive inhibitors
induce a decrease of the 420 nm band and an increase of the
335 nm band. Fig. 5 shows the dichroic spectral changes induced
by compound 37 on human DDC. Analysis of the data at 420 nm
or at 335 nm as a function of inhibitor concentration yields the
following KD values: 17.565.1 mM, 28.263.2 mM, 2.560.7 mM,
4.760.5 mM, 2.460.1 mM, 21.163.5 mM, 25.163.5 mM,
31.763.4 mM, 7.160.9 mM and 1.560.2 mM (inset of Fig. 5) for
compounds 17, 20, 21, 23, 25, 28, 30, 31, 34, and 37,
respectively. These values are in good agreement with the
corresponding Ki values. Unfortunately, the KD values for the
compounds 16, 18, and 24 cannot be measured because of their
low solubility. Like the competitive inhibitors of the first series,
none of these competitive inhibitors alters the absorbance
spectrum of free PLP. In addition, when human DDC complexed
with each of the competitive inhibitors was subjected to extensive
dialysis against 100 mM potassium phosphate buffer, pH 7.4, the
CD spectra of the dialyzed enzymes were identical to that of free
DDC. This clearly indicates a reversible binding mode of these
molecules.
The binding mode of the compounds resulting from the second
screening was also investigated by molecular docking means
(applying the procedure described in ‘‘Materials and Methods
Section’’). This analysis provided us with the following informa-
tion:
Inhibitors (16 and 17) related to compound
5. Compounds 16 and 17 (Fig. 6A) are predicted to have
binding properties very similar to the ones of compound 5. This is
not unexpected given their structural resemblance. However, it
should be noted that (i) the carboxyl group of compound 16 could
form a salt bridge with Arg447, (ii) the benzene ring of compound
17, which replaces the furan ring of compound 5, is predicted to
assume a partial parallel-displaced stacking arrangement with
Phe1039, and (iii) the nitrogen atoms of the 2-carbonyl-2,3-
dihydro-benzimidazole ring of both compounds, which are slightly
translated with respect to compound 5, are hydrogen bonded to
Thr82 and the phosphate group of the PLP cofactor.
Inhibitors (18–37) related to compound 11. All these
compounds are predicted to have binding features very similar to
the ones of compound 11, even if some differences in the
interactions of their hydroxyl groups with the protein and/or the
coenzyme can be noted. In Fig. 6B the predicted binding mode of
compound 37 is shown.
Third Screening
In order to identify molecules with increased activity and obtain
insights into structure-activity relationships, we further expanded
the class of active compounds resulting from the second VS by a
substructure search carried out using the core of the most active
compound 37 (Fig. 7). The OpenBabel substructure search tool
(Open Babel v. 2.3.1, 2011) was used to filter the Ambinter
database of small molecules, using as query the following
SMILES notation (Weininger, 1988): [OH]c2[cH][cH]c(C=
Nn1cnnc1)[cH]c2[OH]. Since the most potent compounds
obtained in the second VS (see compounds 21, 37, 21) have a
catechol ring with meta- and para- hydroxylic groups, the explicit
hydrogens of the unsubstituted benzene carbon atoms and of the
hydroxylic oxygen atoms were included in the SMILES notation
in order to avoid the selection of compounds with substitution
patterns involving these positions.
The substructure search retrieved 73 hits from the Ambinter
database. Among these hits, a series of compounds were selected
based on several criteria including i) commercial availability; ii)
Human DOPA Decarboxylase Inhibitors
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modeling analysis; iii) clustering, based on similarity and
subsequent removal of redundancy. At the end of this step, 10
compounds, whose chemical structures are reported in Fig. 8, were
selected: a compound (38) representing the core of compound 37
and a closely related derivative (39) showing methyl and thiol
substituents at position 3 and 5, respectively, of the 1,2,4-triazole
ring; one compound showing a substitution of the benzene ring for
a smaller furane ring (compound 40); six compounds with different
substitution patterns of the benzene ring (compounds 41, 42, 43,
44, 45, 47); one compound with a methoxy linker between the
1,2,4-triazole and the benzene ring of compound 37 (compound
46). All of them were subjected to in vitro testing.
Inhibition and binding analysis
The inhibition activity of these compounds was evaluated
by human DDC ‘‘in vitro’’ assay. Compound 47 at 200 mM
(the concentration of its maximum solubility) does not inhibit
DDC activity. On the other hand, the IC50 and the Ki values
for competitive inhibition of the remaining compounds have
been determined and listed in Table 4. Dose-response curves
of compounds 39, 40, 41, 42, 43, 44, 45,a n d46 are shown
in Fig. S3B. None of these active compounds binds free PLP but,
when added to human DDC, they cause CD spectral changes
identical to those of compound 37.T h eK D values of
compounds 38, 39, 41, 42, 43,a n d45, determined as above
reported, were found to be 24.564.4 mM, 9.160.3 mM,
Figure 4. Chemical structures of selected compounds from the secondVS screening.
doi:10.1371/journal.pone.0031610.g004
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respectively. These values are very close to the corresponding
Ki. In the case of compounds 40, 44,a n d46,t h ee n z y m e
concentration required for CD measurements far exceeds their
Ki values, which precludes the determination of the KD values of
these molecules.
Ability to cross the Blood-Brain Barrier (BBB) of identified
compounds
All identified inhibitors were analyzed to estimate their ability to
cross the blood-brain barrier (BBB), according to a simple
prediction model developed by Clark et al. [29]. According to
this model, compounds with predicted values of logBB less than
20.3 are not considered capable of crossing the BBB, while values
greater than zero are predictive of concentration in the brain
higher than in the blood. All of the identified inhibitors have logBB
less than 20.3, and ranging from 20.57 to 21.65, highlighting the
poor BBB penetration propensity of these compounds. Moreover,
the most active among the compounds related to 5 and 11, namely
compounds 17 and 44, showed logBB values of 21.24 and 21.30,
respectively, comparable with the one of carbidopa that is equal to
21.50.
Discussion
PD is one of the most common neurodegenerative disorders. It
is characterized clinically by parkinsonism (resting tremor,
bradykinesia, rigidity, and postural instability) and pathologically
by the loss of dopaminergic neurons in the substantia nigra.
Aromatic hydrazine derivatives (e.g., carbidopa and benserazide)
are used in combination with L-Dopa to treat the symptoms of PD
or Parkinson-like symptoms. Being unable to cross the BBB, the
former drugs work by inhibiting only DDC at the peripheral level.
Several side effects (from nausea, hypotension, arrhythmias, and
gastrointestinal bleeding to more serious psychiatric symptoms,
including auditory and/or visual hallucinations, confusion,
psychosis and suicidal thoughts) ensuing from co-administration
of L-Dopa with carbidopa or benserazide have been reported [30].
These adverse effects can be ascribed, at least partially, to the
mode of action of carbidopa and trihydroxybenzylhidrazine (the in
vivo hydrolysis product of benserazide) that, by reacting non-
enzymatically with free PLP, would cause PLP depletion
[18,19,31]. It has also been found that the condensation products
formed between PLP and hydrazine derivatives are the most
potent inhibitors of pyridoxine kinase, an enzyme involved in the
biosynthesis of PLP [32,33]. In addition, it must be pointed out
Table 3. Structural analogs of the most potent hit compounds (compounds 5 and 11) obtained after the first screening.
ZINC-code Ambinter
MW
(Da)
IC50
(mM)
Ki
a
Ki9
b
(mM) BE Inhibition profile
16 03886086 PB-90199554 335 n.d. 59.860.3
a. 12.7 Competitive
17 22621067 PB-251389058 408 16.861.7 4.461.4
a 13.1 Competitive
18 01183789 PB-90040583 365 n.d. 63.263.1
a 11.5 Competitive
19 01183732 PB-90046346 365 n.d. n.d. - n.d.
20 01184616 PB-90047186 365 n.d. 36.864.2
a 12.1 Competitive
21 00550832 STK103726 347 6.360.9 2.360.4
a 16.3 Competitive
22 03044871 STK508886 328 6.760.9 15.160.1
a
46.760.5
b
- Mixed
23 - PB-05713794 312 16.66.3 5.760.1
a 16.8 Competitive
24 00549544 STOCK3S-13636 331 77.162.4 120614
a 11.9 Competitive
25 00520318 STOCK3S-69837 347 15.261.3 3.760.2
a 15.7 Competitive
26 00548914 STOCK3S-09410 347 n.d. 65.2624.1
b 12.1 Nonconmpetitive
27 00344575 STOCK3S-13173 312 n.d. 24.861.2
a
43.161.9
b
- Mixed
28 00554457 STOCK3S-64376 331 17611 4 61
a 14.7 Competitive
29 00553626 STOCK3S-56595 331 n.d. 44.462.3
a
20863
b
- Mixed
30 01478099 STOCK3S-62307 381 29.864.8 12.260.4
a 12.9 Competitive
31 00199179 STOCK3S-19327 296 83612 33.465
a 15.1 Competitive
32 - STOCK3S-20068 523 n.d. 4.560.3
a
1760.2
b
- Mixed
33 00532465 STOCK4S-26311 314 n.d. 16.560.8
a
325639
b
- Mixed
34 00530774 STOCK4S-17596 330 1160.8 10.463.3
a 15.8 Competitive
35 01473651 STOCK2S-87581 381 2962 127616
b - Noncompetitive
36 04898088 STOCK2S-83947 331 n.d. n.d. - n.d.
37 00344577 STOCK2S-84925 312 2.460.3 1.861.1
a 18.4 Competitive
MACCS structural keys system (BIT_packed) and the Tanimoto coefficient were used as fingerprint system and similarity metric, respectively. The table summarizes, for
each compound, the ZINC-code, the Ambinter-code, the molecular weight, the experimental IC50,K i and/or Ki9values, the BE, and the inhibition profile. n.d., not
determined.
doi:10.1371/journal.pone.0031610.t003
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inhibitors show high levels of plasmatic homocysteine [34,35]
found to be inversely correlated with PLP concentrations in the
treated patients [36]. Based on these reports, it is likely that
admnistration of L-Dopa in combination with carbidopa or
benserazide could be responsible for an alteration of the PLP-
dependent metabolism. Thus, there is currently a great interest in
the identification of highly potent, reversible and selective DDC
inhibitors.
A hierarchical filtering approach was used in this work to
identify novel inhibitors of DDC. The hits identified in the initial
VS were tested in vitro on human DDC. This initial information
was used to guide a second round and a third round of VS, in
order to retrieve potentially more potent substances and expand
the new classes of inhibitors, thereby gaining insights into their
structure-activity relationships. In the last years, a lot of effort has
been made to improve the rank order in VS approaches. Often,
compounds are ranked according to their estimated free energy of
binding, and molecular docking is commonly used to this purpose.
However, its high computational cost and required time set an
upper limit to the amount of compounds that can be processed.
One way to solve this issue is to carry out the docking analysis on a
Figure 6. Predicted binding mode of compounds selected after the second VS (similarity search). The figure shows the binding mode of
(A) compound 37 and (B) compound 17. Residues and water molecules interacting with the inhibitors are also shown. Figure was rendered with
Pymol (http://www.pymol.org/).
doi:10.1371/journal.pone.0031610.g006
Figure 5. Visible CD spectral changes induced by compound 37 on human DDC. CD spectra of human holoDDC (—) and in the presence of
the compound 37 at the indicated concentration in 0.1 M potassium phosphate buffer, pH 7.4. Inset: ellipticity change of DDC plus compound 37 at
420 nm and 335 nm as a function of inhibitor concentration. The enzyme concentration was 6 mM.
doi:10.1371/journal.pone.0031610.g005
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Thus, to improve the rank order in VS approaches, pharmaco-
phoric modelling was used in this work, as previously proposed by
others [37,38]. In this way, we were able to select only those
compounds (,10
5), which show the essential chemical features for
DDC binding. During the whole VS process, we didn’t make use
of additional scoring functions as a consensus [39,40,41], other
than the ones implemented in Dovis 2.0 and Autodock Vina.
However we exploited, in addition to docking score criteria, a pose
dependent selection criterium (see ‘‘Materials and Methods
section’’). In this way, final compounds were selected if they 1)
showed a comparable docking pose as obtained by two
independent search algorithms, 2) were top ranking hits, as
assessed by two independent scoring functions, and 3) satysfied the
restraints imposed by the pharmacophore model To our
knowledge, the VS protocol that we used, in which Pharmaco-
phore-Based Virtual Screening is integrated as a pre-processing
and post-processing step with the main docking-based virtual
screening step, has never been applied before. Notably, it resulted
in a high success rate (5 active compounds out of 15) during the
initial in vitro testing on human DDC. Such complex VS approach
outperformed simpler approaches such as 2D similarity or
substructure searching. In fact, when the latter were used with
carbidopa as query (by the MACCS structural keys and the TC as
fingerprint systems and similarity metric, respectively) on the same
drug-like and lead-like subsets, compounds 1, 2, 5 and 11 were
ranked, according to TC, in positions $7.5610
5. Therefore, they
would have not been identified.
By means of our VS approach we identify three new classes of
compounds acting as competitive human DDC inhibitors: (i)
compounds 1 and 2, (ii) compound 5 and its analogs, and (iii)
compound 11 and its analogs. These classes show scaffolds
composed by two differentially substituted aromatic cycles,
connected by a rigid hydrophobic linker with an electron-rich
group. The first aromatic ring is represented by a catechol ring
(compound 11 and its analogs), or a 2-carbonyl-2,3-dihydro-
benzimidazole (compound 5 and its analogs) or a hydroxybenzo-
triazole (compounds 1 and 2) bicyclic ring. The linker is
represented by a 4-N-[3-mercapto-1,2,4-triazol-4-yl]-carboximi-
doyl moiety (compound 11 and analogs) or a sulfonamidic group
(compounds 1, 2, 5 and its analogs). The second ring is
represented by a substituted chloro-benzene ring (compound 11
and analogs), or a piperidine ring (compound 2), a carboxy-
benzene ring (compounds 1 and 16), a 2-(((furan-2-yl)-methyla-
mino)-carbonyl)-benzene ring (compound 5) or a 2-(((phenyl)-
amino)-carbonyl)-benzene ring (compound 17).
When taking into account the chemical structure as well as the
inhibition and binding data of the compounds, simple structure-
activity observations can be derived. For molecules related to
compound 5, the substitution of the furan-2-yl-methyl moiety with
a benzene ring results into an about 13-fold increase of affinity
(compare compounds 5 and 17), while the substitution of the
furan-2-yl-methylamino-carbonyl moiety with a carboxylic group
does not improve affinity (compare 5 and 16). For the molecules
Figure 7. Core of compound 37. The core of compound 37 was
used as a query (the Smiles annotation string used is shown in the text),
using OpenBabel, to filter the Ambinter database. Positions where no
substitutions were allowed during the search are coloured in red.
doi:10.1371/journal.pone.0031610.g007
Figure 8. Chemical structures of selected compounds from the thirdVS screening.
doi:10.1371/journal.pone.0031610.g008
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two hydroxyl substituents from the ortho-meta to the meta-para
positions results in compounds with comparable binding affinity
(compare compounds 11 and 30), (ii) the removal of chlorine
subtituents from the ortho-meta) hydroxy-substituted compound
(compound 11) results in a decrease of Ki (compare compounds 11
and 23), (iii) the removal or substitution of one or two chlorine
subtituents from the meta-para hydroxy-substituted compound
(compound 30) results in a decrease in Ki values in the following
order: compounds 30 (ortho-para-Cl)<34 (para-F).25 (ortho-
Cl).21 (para-Cl)<37 (unsubstituted), (iv) the removal of a
hydroxylic group from the ortho-meta (compound 11)o rmeta-para
(compound 30) hydroxy-substituted compounds results in a
increase of Ki in the following order: compound 11< compound
30,compound 20 (meta-hydroxy),compound 18 (para-hydro-
xy),compound 19 (ortho-hydroxy, poorly active), (v) the removal
or substitution of chlorine from the mono-ortho-hydroxy (com-
pound 19) and mono-meta-hydroxy (compound 20) compounds
results in compounds either of different affinity (compounds 24,
28, 31, 36) or different inhibition profile (compounds 29, 32, 33).
Among those showing a competitive inhibition profile, compound
31 (unsubstituted) and compound 28 (ortho-Cl) are the most potent,
and (vi) the presence of a hydroxylic-substitution pattern different
from that of the catechol moiety, ortho-meta or meta-para,o ro fa
mono hydroxylic-substituted ring, results in a deviation from the
competitive inhibition profile, i.e., mixed (compounds 22, 27, 32)
or noncompetitive (compounds 26 and 35) inhibition.
According to their predicted binding mode (see results) the three
classes of active compounds share some or all of the following key
interactions: (i) cation - p interaction with Lys303 and one or two
hydrogen bonds with the phosphate of PLP, Thr82 or the
carbonyl of Pro81; (ii) hydrogen bond interactions with the active-
site water network and/or with His192; (iii) stacking interaction
with Phe1039; (iv) hydrophobic interactions with Tyr79, Phe80,
Thr246 and Leu3539. The hydrophobic interactions with Tyr79,
Phe80, Thr246 and Phe1039 represent two new pharmacophoric
features of our developed structure/ligand-based pharmacophore
model, and it is noteworthy that the compounds 17, 21, 23, 25,
and 37 showing the lowest Ki (,10 mM) fulfill all these binding
requirements, while, compound 2, missing several key interactions,
exhibits the highest Ki value (Ki=390 mM). It should be noted
that in the spatial structure of ligand free DDC and its complex
with carbidopa a flexible loop between residues 328 and and 339 is
invisible in the electron density map [13]. Limited proteolysis and
site-directed mutagenesis data have indicated that substrate-
induced conformational changes occur at this loop and that its
closure is an essential step in the decarboxylation mechanism
[4,42]. On the basis of our docked pose it is predicted that this
conformationally dynamic loop forms a cleft that accommodates
the benzene ring of compound 37 and its derivatives. Although the
lack of structural information on this loop does not allow the
rational design of this part of the molecule to improve the binding
efficiency, the results of out third VS allow to draw some
conclusions about the influence of the cleft on inhibitor binding
and its ability to accommodate different chemical groups. In
particular, we noticed that: (ii) the presence at the 5 position of the
thiol substituent, which is predicted to interact via hydrogen-bond
with the phosphate tail of PLP, improves binding efficiency as can
be appreciated by comparing compound 38 and 39, (ii) the
substitution of the benzene ring for a smaller furane has only
minimal influence on activity (compare compounds 37 and 40),
(iii) the analysis of compounds in which the benzene ring is
decorated with a methyl (compounds 41, 42, 43) or a methoxy
substituent (compounds 44, 45 and 47)i northo-, metha- and para-
positions, respectively, allows to infer that, although the cleft is able
to accommodate compounds bulkier than 37, a net preference of
metha- and para- over ortho- substitutions could be observed.
In conclusion, this research has allowed the identification of
compounds which are predicted do not cross the BBB, and, unlike
carbidopa and thrydroxybenzylhydrazine (the in vitro hydrolysis
product of benserazide) behave as reversible competitive inhibitors
with Ki values in the low micromolar range. The most potent
inhibitor binds human DDC with a Ki of 500 nM. Moreover, the
finding that they do not interact with free PLP allows us to
envisage that these inhibitors could have an intrinsic chemical
reactivity lower than that of carbidopa and the metabolic product
of benserazide. Thus, the compounds identified and tested here
may provide precious guidelines for the drug development process
for the PD therapy.
Materials and Methods
Materials
L-Dopa, PLP, 2,4,6-trinitrobenzene-1-sulfonic acid, isopropyl-
b-D-thiogalactopyranoside, protease inhibitor cocktail (P8849)
were Sigma products. DDC inhibitors were purchased from
Ambinter (Paris, France). Purity (90% or higher) of these
compounds was confirmed on the basis of NMR and/or LCMS
data provided by vendors. All other chemicals were of the highest
purity available.
Databases of chemicals
The drug-like and lead-like subsets of the ZINC database [21]
were downloaded and used to generate low-energy conformations.
The ‘‘Conformation import’’ function of MOE (The Molecular
Operating Environment; Chemical Computing GroupH, Mon-
treal, Canada) was applied to this purpose. For each compound,
the following settings were applied here and thereafter, if not
otherwise stated: maximum 250 conformers for each compound;
no input filters used; constraints options kept at their default
values; only the conformers with strain energy less than 4 kcal/
mol retained.
All of the compounds of the training set [20] were built with
MOE, energy minimized using the mmff94x force field, and used
to build a series of energetically plausible conformations. A set of
Table 4. Structural analogs of the most potent hit compound
(37) obtained after the second screening.
Ambinter
MW
(Da)
IC50
(mM)
Ki
(mM) BE
38 Amb1808242 204 76.065.8 24.561.4 22,6
39 Amb8754110 250 27.563.3 10.860.8 19,9
40 Amb666646 302 3.560.2 1.460.1 19,4
41 Amb5967895 326 30.162.1 9.860.5 15,4
42 Amb655238 326 5.260.4 2.060.2 17,5
43 Amb685531 326 3.860.6 1.960.1 17,5
44 Amb2470350 342 1.760.2 0.560.1
a 18,4
45 Amb2472735 342 6.260.3 2.060.1
a 16,7
46 Amb666103 342 3.560.3 1.160.1 17,4
47 Amb782700 342 .200 n.d. n.d.
The table summarizes, for each compound, the Ambinter-code, the molecular
weight, the experimental IC50,K i9 values, and the BE. n.d., not determined.
doi:10.1371/journal.pone.0031610.t004
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L.L.C., New York), was imported in MOE and series of
energetically reasonable conformations were generated for each
compound, using the ‘‘conformation import’’ function of MOE.
Therefore, the final training set is composed by the union of the
initial training set plus decoys.
Target preparation
Since a potential competitive inhibitor is expected to bind to the
internal aldimine of DDC, we made use of PDB structure 1JS6 for
pharmacophoric modeling purposes. To this end, 1JS6 was
structurally aligned to 1JS3 using the ‘‘MOE-ProSuperpose
function’’; then, we manually inserted carbidopa into the active
site of 1JS6, on the basis of the 1JS3 structure. The obtained
complex was visually inspected in order to verify the absence of
steric clashes between carbidopa and the residues at the active site.
Pharmacophore Model generation
Pharmacophore modeling calculations were performed using
MOE. The MOE PQ function was used in order to build the PH
starting from the 1JS6 – carbidopa complex. The ‘‘Unified
Annotation Scheme’’ was used to assign the pharmacophoric
annotation points (such as H-bond donor, H-bond acceptor,
hydrophobic). Chemical features (coordinates, type of chemical
feature and sphere radius) corresponding to atoms or groups of
atoms of carbidopa were inserted in the PH. MOE’s default values
for the radii of atom-based chemical features (1 A ˚) and projections
(1.4 A ˚) were used. An excluded volume, comprising residues at the
active site of DDC located within a radius of 15 A ˚ from any atom
of carbidopa, was inserted in the PH.
The active compounds of the training set were analyzed by PS
using the PH. During each PS the ‘‘partial match’’ option was
activated and the number of chemical features to be matched was
always set to ‘‘at least three’’ (default setting, if not otherwise
stated). The aromatic centroid feature of the catechol ring of
carbidopa was set as ‘‘essential’’. For each compound, all of the
matching conformations were selected. For each of the selected
conformation, the number of matched features and the RMSD
between the centers and the corresponding annotation points were
derived. The conformations for each selected compound were
sorted by decreasing number of matched features and increasing
RMSD; for each compound only the highest ranked conformation
was selected. This procedure was applied also in the following PSs.
Of the 71 active compounds analyzed, all satisfied the restraints
imposed by the PH, and they were subsequently subjected to the
‘‘pharmacophore consensus function’’ of MOE. The ‘‘pharmaco-
phore consensus function’’ suggests, from a set of structurally
aligned molecules, common chemical features (coordinates, radius
and feature type) that can be in turn inserted in a PH. When the
‘‘pharmacophore consensus function’’ was used, the following
settings were applied: tolerance radius set to 1, the consensus score
set to ‘‘weighted conformations’’ and the threshold set to 30%.
Thus, the PH was modified according to the new data obtained
from the pharmacophore consensus analysis: new identified
features were added to the PH and the radii of the spheres of all
the chemical features were increased/decreased accordingly.
In order to assess which feature of the PH should be regarded as
essential for the subsequent PSs, we generated several alternative
PHs, by discharging each time one feature. Then, we evaluated
each PH for its ability to rank active and inactive compounds. To
this end, we first derived a new dataset of compounds, merging the
training set and the decoys. Then, for each PH, we measured the
fraction of active and inactive compounds that were present
amongst the best 3.46% ranking hits (corresponding to the ideal
situation, in which all 71 active compounds are ranked in the first
71 positions of the ranked hits), according to the PS. When the PH
with all the chemical features was used, 48% of the active
molecules and 10% of the inactive molecules of the training set
were retrieved in 3.46% of the top ranking hits. Among the
generated alternative PHs, the one showing the highest decrease in
terms of retrieved active compounds lacked the C9 feature.
Moreover, the PHs showing the highest increase in terms of
retrieved inactive compounds were those lacking F3 (16%) and
C10 (16%).
Finally, to verify the effects of the changes brought to the PH in
the previous steps, we evaluated the ability of the PH to rank active
and inactive compounds when used with its initial settings (derived
from the 1JS6 – carbiDOPA complex) and with the final settings
(see Table 1). To this end, the same database was used as before
and we measured the fraction of active (poorly active, moderately
active and highly active) and inactive compounds, which were
present amongst the best 3.46% ranking hits, according to the PS.
Docking settings
The drug-like and lead-like compounds retrieved from the PS
were docked into the active site of DDC. To this end Dovis 2.0
[23,24] was applied. Initially, the complex PLP-carbidopa was re-
docked in the active site of DDC (PDB code: 1JS3), in order to
optimize the parameters of the docking program to be used during
the high-throughput docking. To this end, 1JS6 was structurally
aligned to 1JS3 using the ‘‘MOE-ProSuperpose function’’; then,
we manually inserted carbidopa into the active site of 1JS6, on the
basis of the 1JS3 structure. The obtained complex was visually
inspected in order to verify the absence of steric clashes between
carbidopa and the residues at the active site. To this end, an
energy grid with 40640640 (numbers refer to the number of grid
points in xyz), centered on the e-amino group of the active site
Lys303 of pig kidney DDC, and a 0.375-point spacing was used.
Atom-specific affinity maps were then computed for each atom
observed in the ligand, and a distance-dependent dielectric
constant was adopted. Several docking simulations were initially
run. During each simulation, grid dimension and center values
were systematically varied, while other parameters were main-
tained at their default values, in order to find which combination
of values was able to reproduce the binding pose of carbidopa
bound to PLP present in the three dimensional structure. The
selected values for grid dimensions and center were respectively
36636636 and x=43.573 y=37.127 z=68.616 (coordinates are
referred to the 1JS3). During the high-throughput docking, the
Lamarckian Genetic Algorithm was chosen as search algorithm,
using the following values: number of individuals in population,
150; maximum number of energy evaluation, 250000; maximum
number of generation, 27610
3; rate of gene mutation, 0.02. Water
molecules were excluded from the docking calculations. All other
parameters were kept at their default values.
After initial parameter optimization, the active compounds of
the training set plus decoys were docked in the active site of DDC
by means of Dovis 2.0, and ranked according to their predicted
energy of binding. Only 11% of highly active compounds were
retrieved within approximately the first 15% of the screened
database. Then, in an attempt to improve the docking step, we
applied a procedure involving two independent docking tools
(Dovis 2.0 and AutoDock Vina), and we considered only those
compounds showing a similar pose (RMSD,2A ˚). Moreover,
compounds were ranked according to the mean of their predicted
energy of binding. By applying this second approach, 44% of
highly active and only 3% of inactive compounds were retrieved
within approximately the top-ranking 15% of the screened dataset.
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protocol.
When Autodock Vina [25] was used, the same grid parameters
described previously were adapted, the exhaustiveness option was
set to 8, and all other options were kept at their default values.
Since a potential competitive inhibitor is expected to bind to the
internal aldimine of DDC, we made use of PDB structure 1JS6 for
subsequent docking purposes.
Post-filtering phase
A post-filtering step, based on the initial PH hypothesis, was
coupled to the main docking-step. The latter, introducing
additional structural knowledge on the ‘‘hot spots’’ of the active
site, increased the performance of the VS protocol. Indeed, when
the training set plus decoys was analyzed by the complete VS-
protocol (docking plus pharmacophore search), 44% of highly
active, 10% of moderately active, 3% of poorly active and 6% of
inactive compounds were ranked in the top 0.6% of the screened
database.
During the post-filtering phase, the poses of the docked drug-
like molecules obtained in the previous docking-based virtual
screening step were ranked according to their score, obtained with
the scoring function [24] implemented in Dovis 2.0. The mean
and standard deviation of the scores were then calculated, and
those compounds scoring at .2 standard deviation from mean
were selected and re-docked with Autodock Vina. Only those
compounds showing a similar (RMSD,2A ˚) docked pose, as
assessed by Dovis 2.0 and AutoDock Vina, were kept. Finally, the
selected poses were filtered with the previously developed PH with
the ‘‘absolute position’’ option activated. In this way, when
analyzed during PS, the poses were not allowed to be translated or
rotated, and only those in agreement with the PH were kept. Lead-
like molecules were processed similarly.
Assessment of the binding efficiency (BE) and BBB of
selected compounds
When assessing the druggability of newly identified molecules, it
is useful to monitor their molecular weight. This parameter relates
to a contrasting trend: (1) an important increase in molecular
weight is often required to reach the appropriate level of potency,
(2) key properties that determine the druggability of a molecule
tend to worsen when the molecular weight increases over a certain
point [43]. Therefore, when establishing the viability of a molecule
both potency and molecular weight need to be monitored and well
balanced. The concept of BE represents a suitable means of
assessing this relationship; it is, for a given compound, a measure
of the binding energy per unit of mass relative to its target. Several
definitions have been proposed, but throughout this work the
following has been be used:
BE~pKi=MolecularWeight ð1Þ
being Ki expressed in molarity (micromoles/L), and the molecular
weight in kDa. It has been observed that 90% of lead molecules
and drugs have efficiencies above 12.4 and 14.7, respectively [43].
All identified inhibitors were analyzed to estimate their ability to
pass the BBB according to a simple prediction model developed by
Clark [29], which takes into account the octanol/water partition
coefficient (logP), calculated according to Moriguchi (MlogP; [44]),
and the topological polar surface area. Moreover, values for
MlogP topological polar surface area were calculated using the
AlogPS online software [45] and MOE, respectively. Predicted log
BB was calculated using the formula:
LogBB~({0:0145TPSA)z(0:172MlogP)z0:131 ð2Þ
Compounds with predicted values of logBB less than 20.3 are not
considered capable of crossing the BBB, while values greater than
zero are predictive of concentration in the brain higher than in the
blood.
Expression and Purification of Human DDC
Human DDC was expressed and purified by mean of the
procedure previously described [46]. The enzyme concentration
was determined by using an eM of 1.3610
5 M
21 cm
21 at 280 nm
[26]. PLP content of wild-type was determined by releasing the
coenzyme in 0.1 M NaOH and by using eM=6600 M
21 cm
21 at
388 nm.
Assay of the inhibitory activity
DDC activity was determined by measuring the production of
dopamine with a spectrophotometric assay outlined by Sherald et
al. [47] and modified by Charteris and John [48]. The reaction
was carried out in 0.1 M potassium phosphate buffer pH 7.4 at
25uC for 1 min and stopped by inactivation of the enzyme at
100uC for 90 sec. The inhibitory assay was performed by
measuring the decarboxylase activity of DDC with 50 nM
enzyme, 0.1 mM L-Dopa, and 10 mM PLP in the presence and
in the absence of a fixed amount of each compound. Various
amounts of dimethyl sulphoxyde (DMSO) were necessary to
solubilize the compounds in 100 mM potassium phosphate buffer,
pH 7.4. In any case, the final DMSO concentration in the assay
mixture was kept lower than 1% (v/v), i.e., under experimental
conditions in which decarboxylase activity is not affected. Dose-
response curves were generated to determine the concentration
required to inhibit 50% of decarboxylase activity (IC50).
Compounds were evaluated at 9 concentrations, and each in
duplicate. IC50 values were derived by nolinear regression analysis.
The related inhibition type of the compounds on human DDC was
identified from Lineweaver–Burk plots, and Ki and/or Ki9 values
for the inhibitors tested were calculated by the software Origin 7.0.
Enzyme-ligand equilibrium dissociation constant (KD)
The equilibrium dissociation constant for each tested compound
from DDC was determined by monitoring the decrease in the
420 nm CD signal of DDC (7 mM) in the presence of various
ligand concentrations in 100 mM potassium phosphate buffer,
pH 7.4. In any case, the maximun DMSO concentration in the
mixture was kept lower than 1% (v/v). The KD values were
obtained from the fitting of the data to the equation
Y~YMAX|
½E tz½L tzKD{
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(½E tz½L tzK2
D{4½E t½L t)
q
2½E t
where [E]t and [L]t represent the total concentrations of DDC
dimer and ligand, respectively, Y refers to the visible CD signal
change at 420 nm at the ligand concentration [L], and Ymax refers
to the CD signal when all enzyme molecules are complexed with
the ligand. CD measurements were performed with a Jasco J-710
spectropolarimeter using quartz cuvettes with 1 cm path length.
Supporting Information
Figure S1 Normal distribution plot of predicted pKi
values for drug-like molecules. 280000 drug-like molecules
were docked in the active site of DDC with the Dovis 2.0 docking
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PLoS ONE | www.plosone.org 13 February 2012 | Volume 7 | Issue 2 | e31610tool [23,24] and the distribution of their predicted pKi was
derived. The normal distribution showed a mean pKi of
5.5760.81.
(TIF)
Figure S2 Normal distribution plot of predicted pKi
values for lead-like molecules. 180000 lead-like molecules
were docked in the active site of DDC with the Dovis 2.0 docking
tool [23,24] and the distribution of their predicted pKi was
derived. The normal distribution showed a mean pKi of
5.3060.62.
(TIF)
Figure S3 Dose-response curve of the most potent
compounds. (A) Compounds obtained from the first and the
second screening indicated with the following colors: black,
magenta, light green, blue, orange, dark green and red, for
compound 11, 17, 21, 23, 25, 34 and 37, respectively. (B)
Compounds obtained from the third screening indicated with the
following colors: dark green, purple, orange, magenta, blue, black,
red and light green, for compound 39, 40, 41, 42, 43, 44, 45 and
46, respectively. Data were fitted using the standard IC50 equation
with Origin 7.0 software (OriginLab).
(TIF)
Table S1 Ranking of the drug-like compounds, as assessed by
VS protocol.
(DOC)
Table S2 Ranking of lead-like candidates, as assessed by VS
protocol.
(DOC)
Table S3 Ranking of selected compounds, obtained by applying
the similarity search of the entire ZINC database (,9.0610
6
compounds), using compound 11 as query.
(DOC)
Table S4 Ranking of selected compounds, obtained by applying
the similarity search of the entire ZINC database (,9.0610
6
compounds), using compound 5 as query.
(DOC)
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